PDCD1 and hepatocellular carcinoma: These results demonstrate that PLAUR<sup>+</sup> neutrophils serve as a critical regulator of immunotherapy resistance and targeting PLAUR is a promising strategy to augment the efficacy of anti-PD-1 therapy in HCC.